Safe Fertility Group Public Company LimitedSET: SAFE🇹🇭 TH

Risk Management · 2025

Risk Management Policy & Plan

Policy & Plan Description

The Company is dedicated to effectively managing risks that impact the achievement of organizational objectives. This encompasses the management of security risks, health, and hygiene risks of employees in accordance with international standards, compliance with laws, regulations, and operational standards, and adherence to relevant operational guidelines. The Company responds fairly to stakeholders while considering the performance goals and investments of the Group in both the short and long term, consistent with principles of good corporate governance. This approach aims to minimize the likelihood of potential risks or damages, and to seize business opportunities, while creating sustainable value for the business. To ensure clarity in the Company's risk management, the management establishes the following guidelines.

  1. The Company will establish a system and process for enterprise-wide risk management that aligns with the business strategies and objectives, in accordance with international standards.

  2. The Company will maintain risks at an acceptable level or ensure that the deviation of risks from the established level will not exceed the level acceptable to the Company.

  3. The management will supervise the Company's risk management, ensuring compliance with the policy, conducting screenings, providing feedback, suggestions, and monitoring to enhance the efficiency and effectiveness of risk management. The management must also reportany significant risks that may severely impactthe Company's business operations to the Audit Committee and the Board of Directors and seek appropriate remedies.

  4. The Board of Directors must oversee and manage risk within the organization and approve remedial measures.

  5. The management oversees the risk management across the Group and monitors the management of each risk in accordance with their responsibilities. This includes ensuring that the management aligns with the Company's various policies and regularly providing reports on risk management performance to the Board of Directors for their approval or feedback, as appropriate.

  6. Executives across all departments of the Company must manage risks at the organizational, functional, and operational levels, either through their designated responsibilities or as assigned by management. They must also report operational outcomes in the formats and guidelines specified by management. Additionally, they are encouraged to promote employee awareness of the importance of risk management.

  7. The management must provide advice, opinions, suggestions, and guidelines n risk management to various departments within the Company and regularly report to the Board of Directors or as appropriate.

  8. All employees must comply with the Company's risk management systems and processes at the organizational, functional, and operational levels as determined by the Company or management.

  9. Each year, the internal auditors or internal audit department must audit internal controls and verify operational risks within the Company.

Risks to the Company's Business Operations

Risk Register

Risk NameRisk CharacteristicsConsequencesManagement MeasuresRelated Risk Factors
Risk of competition in the infertility treatment business

Currently, the infertility treatment services tend to be more intensely competitive. As the incumbent operators improve their service quality and increase their reputation. And as new operators are gradually entering the market, causing the market share to be taken from the existing operators. As a result, there is an awareness of service competition and the use of pricing policies to attract customers. In addition, the impact of trade and service liberalization under the agreement of the ASEAN Economic Community (AEC) may result in new competitors within ASEAN countries expanding their service scope into Thailand. These competitive factors may inevitably affect the Company.

  1. The increase in the number of service providers, including hospitals, specialized clinics, and new market entrants, may intensify competition in attracting patients. This could result in a decline in the Company’s patient volume or market share and may adversely affect overall business revenue.

  2. Heightened competition may also lead service providers to reduce prices or offer promotional campaigns to attract customers, which could negatively impact profit margins.

  3. The Company may need to increase its budget for marketing, public relations, branding, and customer access channels in order to retain existing customers and attract new ones.

  4. Competition in the IVF industry is often driven by advanced medical technologies, treatment success rates, and the expertise of medical professionals. Therefore, the Company may need to invest further in medical technologies and laboratory facilities, which could lead to higher operating costs.

When compared to other infertility treatment centers in the market, the Group has many competitive advantages. Both in terms of the long-established reputation, location, as well as the quality and modern service standards of the Group.

The Company acknowledges the risk of competition and has therefore established a quality policy for efficient organizational development. The risk management policy aims to establish a sustainable competitive advantage, including access to services in branches located in key tourist destinations within the country. This is done to cater to consumer needs and ensure their access to the services provided by the Group. The quality policy encompasses advancements in medical practices, compliance with relevant laws, regulations, and requirements, and emphasizes the provision of comprehensive services through innovative approaches. The development of staff capabilities to meet consumer demands is also prioritized. Based on this organizational development policy, the Company believes it can effectively create a sustainable competitive advantage.

1714 · Description: Competition risk · Info category: STRATEGIC_RISK
Risk of reliance on distributors for drugs, medical supplies, tools, equipment, and reagents used in laboratory analysis.

The Company procures drugs, medical supplies, tools, equipment, and reagents used in laboratory analysis from multiple partners. The majority of these trading partners are domestic manufacturers or major distributors specializing in the distribution of certified products, including pharmaceuticals and high-quality medical equipment. As the industry norms, pharmaceutical companies do not engage in self-distribution. Therefore, drugs and medical supplies are sometimes purchased from various companies. Consequently, the Company may face risks associated with relying on these distributors.

  1. If suppliers are unable to deliver products as scheduled, or if shortages occur in medications, medical supplies, or laboratory reagents, certain medical services or diagnostic procedures may be delayed or unable to proceed as planned.

  2. Price volatility or increases imposed by suppliers may result in higher costs for medications, medical supplies, equipment, and reagents, which could adversely affect the Company’s profit margins.

To effectively manage the risk of relying on manufacturers or distributors in the future, the Company has implemented a procurement policy for pharmaceutical products and medical supplies. The policy includes sourcing from domestic manufacturers or distributors representing foreign manufacturers who meet the Company's standards. Additionally, an Approved Vendor List has been created, considering various factors such as licensing and certification requirements, including ISO, CE, or TIS certifications, as well as compliance with regulations set by the Food and Drug Administration (FDA). Thailand has the capability to procure high-quality pharmaceutical products and medical supplies that are renowned and meet the requirements of healthcare professionals. The Company's selection criteria also consider the supplier's financial stability and adherence to standardized delivery systems. Notably, the Company has not had any exclusive or unique contractual obligation regarding the procurement of medicines, medical supplies, medical materials, or medical devices with any specific supplier.

The Comapny is confident in its ability to effectively manage the risks associated with purchasing pharmaceutical products, medical supplies, and analytical reagents for laboratory analysis. This is due to the Group's history of establishing and maintaining strong relationships with manufacturers of pharmaceuticals, medical supplies, and laboratory analytical reagents. The Group ensures timely and complete payments, consistently adhering to its procurement policies. The Group has a dedicated department responsible for systematically and continuously overseeing risk management in this area. Regular discussions and meetings are conducted to monitor inventory levels and proactively plan future orders for pharmaceuticals, medical supplies, and medical devices. Additionally, the Group maintains positive relationships with other distributors, allowing it to source drugs and medical supplies from alternative suppliers beyond those previously mentioned. Consequently, the Group has never encountered any issues or shortages in ordering pharmaceutical products, medical supplies, and analytical reagents for laboratory analysis in the past.

735 · Description: Reliance on large partners / distributors or few partners / distributors · Info category: STRATEGIC_RISK
Risk from the impact of other epidemic situations or situations similar to COVID-19

The outbreak of infectious diseases may adversely affect the overall economy, tourism, and patients’ confidence in seeking treatment at the Company’s fertility clinics. This could, in turn, negatively impact the Company’s operating results, financial position, and business opportunities.

The outbreak of COVID-19 in the past had a significant impact on the Company’s international customers, who represent a key customer segment. As a result, the Company’s operating performance was materially affected.

During the epidemic, the Company's executives and relevant departments closely monitored news that may impact the Company, allowing them to develop appropriate response plans if a communicable disease were to occur. This includes building a positive image that instils confidence in using the services provided by the Company's infertility treatment centers. Specific measures are implemented to ensure the safety of customers, such as requiring the use of masks throughout working hours and scheduling appointments appropriately for each patient. Additionally, medical equipment and operating rooms are properly conducted to comply with established standards.

Additionally, amidst the COVID-19 epidemic and travel restrictions that significantly affected the influx of foreign customers seeking services from the Group, the Company has adjusted its business strategy to align with the prevailing circumstances. By targeting the local Thai customer base during this period, the Company could mitigate the impact to a considerable extent and generate a net profit from its operations amidst the COVID-19 outbreak.

Currently, the COVID-19 epidemic situation in Thailand is gradually improving, leading to increased relaxation of entry measures as the country reopens to international tourists. Consequently, foreign customers have begun to return and use the services. However, the Company remains vigilant, closely monitoring news that may impact its operations in order to effectively manage business activities according to the established operational plan.

1718 · Description: Pandemic risk · Info category: STRATEGIC_RISK
Risk of compliance with relevant laws, regulations, and guidelines related to the business

As a business operator engaged in providing medical assisted reproductive technology services, laboratory analysis services, genetic disease screening, and beauty clinic services, the Group must obtain a business license from the relevant authorities and comply with applicable laws, regulations, and various standards. This includes the Act on the Protection of Children Born Using Assisted Reproductive Technologies, B.E. 2558 (2015) and relevant regulations, as well as other government agencies responsible for regulating licenses or standards necessary for the Company's operations, such as the Sanatorium Act, B.E. 2541 (1998) (as amended) and the Medical Device Act, B.E. 2551 (2008) (as amended). The Company must also adhere to any periodic license renewal requirements specified in announcements by the Ministry of Public Health. Changes or amendments to current laws, regulations, rules, and announcements, or the introduction of new regulations, may impact the Company's operations, necessitating additional actions. Interpretation of current laws, regulations, rules, and announcements, as well as the promulgation of new laws or regulations, indicates a trend towards increased stringency. These developments may impact the Company's operations.

The Company is exposed to the risk of non-compliance with laws and regulations related to Assisted Reproductive Technology (ART), which may result in license revocation, legal actions, loss of revenue, diminished patient confidence, and a material impact on the continuity of the Company’s operations.

The Group recognizes the significance of adhering to announcements, regulations, and relevant laws, and prioritizes compliance with applicable announcements, rules, regulations, and laws. It has a policy in place to ensure that responsible personnel actively and consistently monitor, inspect, attend training sessions, and seminars to stay informed about the Company's medical business operations as provided by the government. This enables the Company to comply with announcements, rules, regulations, and relevant laws accurately and to meet the established standards. Furthermore, it emphasizes that responsible personnel must ensure that the Company obtains and maintains the licenses required for its business operations. They must also ensure that there are no grounds to revoke these licenses. The management team will adhere to various regulatory requirements, including newly issued regulations, to effectively plan the Company's business operations and adapt to any necessary changes promptly. This approach enables uninterrupted business operations.

756 · Description: Change in laws and regulations · Info category: COMPLIANCE_RISK
Risk of being sued for damages arising from medical services or the risks involved in patient care, including symptoms or complications from surgery or procedures

The Group prioritizes quality treatment and meeting patient expectations. However, each patient has different expectations, and treatment outcomes vary depending on the individual. Failure to meet patient expectations puts the Group at risk of treatment outcomes falling short of expectations.

This could lead to patient criticism on social media, complaints to relevant agencies, and potential legal action. Therefore, the Group is at risk of being sued due to patient dissatisfaction with the treatment outcomes or potential implications related to the medical care provided by the physicians and specialists within the Company. The Group and/or the physicians may be required to compensate the claimant, which can impact the future performance and reputation of the Group.

The Group has consistently developed the quality of its services, prioritizing safety. This includes selecting experienced and skilled physicians and personnel, establishing policies and procedures for treatment, assessing the patient's mental condition, and obtaining clear and explicit consent through documents such as consent letters that specify the relevant laws or regulations. Additionally, the Group regularly assesses the quality of service, particularly in medical treatment and patient satisfaction when customers receive services and treatment from the Group. These measures allow the Group to continuously monitor operational efficiency and the quality of service delivery. The established procedures also indirectly aim to prevent potential legal claims and various damages that may occur. The processes are also implemented, controlled, and monitored within a consistent framework, process, and policy across all service branches. This is to maintain the Group’s uniform service quality standards. It involves regular training for personnel based on their roles and responsibilities to enhance their skills and expertise in their work. Furthermore, the Group has established a risk management working group to comply with sound corporate governance principles. Their role is to identify, assess, and monitor risks, as well as manage them effectively, to minimize potential risks systematically and efficiently.

In 2025, the Group had no lawsuits claiming damages resulting for medical treatment services that had any significant impact on the Group.

1723 · Description: Legal risk · Info category: COMPLIANCE_RISK
Risk of a shortage of skilled physicians or medical personnel

The Group’s business operations rely on medical personnel who possess knowledge, abilities, and specialized expertise in various fields, including physicians, nurses, pharmacists, and embryo culture scientists. Therefore, there may be a shortage of personnel, which could impact the Group's business operations. Specifically, physicians must have specialized knowledge in reproductive technology, while scientists need specific skills for processes such as laser procedures, egg drilling, sperm insertion, and egg selection. Currently, personnel with these skills are limited.

The Group may face future challenges due to a shortage of these personnel.

Historically, the Group did not experience any shortage of personnel. The average employee turnover rate in the Group was 0.67% in 2025. Acknowledging the significance of medical personnel, the Group has implemented a talent management policy. This includes the following incentives.

1) The Group recruits personnel with knowledge, skills, experience, and values that align with the Group's organizational culture, both through its own recruitment channels and in collaboration with external agencies.

2) The Group establishes compensation, welfare, and benefits that are commensurate with the individual's experience, knowledge, and abilities, and can be compared to those offered by other companies.

3) The Group prioritizes personnel development and provides career pathways that support employees in all positions. It encourages further studies relevant to their roles and responsibilities and ensures regular participation in training programs and site visits organized by both internal and external entities, including educational and research institutions, both domestically and internationally. Moreover, Group personnel may also serve as consultants or trainers, sharing their knowledge with individuals both domestically and internationally.

4) The Company evaluates its employees and makes necessary adjustments to ensure that compensation, welfare, and performance benefits are commensurate with employees' abilities and job positions. This approach aims to motivate employees and encourage their personal development.

5) The Group regularly reviews its manpower plan to ensure a continuous supply of knowledgeable, skilled, and experienced personnel who are ready to fulfil their roles effectively. It also establishes a succession plan for key positions, considering performance and potential, particularly in leadership, and alignment with corporate values.

739 · Description: Shortage or reliance on skilled workers · Info category: OPERATIONAL_RISK
Risk associated with technological advancements in medical instruments and equipment

The Company’s infertility treatment services rely on state-of-the-art medical and laboratory equipment.

The rapid advancement of medical technology may impact the Company's financial position, operating results, and business prospects, as well as customer satisfaction and future customer demands.

The Company's executives and working group continuously monitor news and advancements in medical technology related to assisted reproductive technology. They also assess the necessity and suitability of adopting new, efficient technologies that adhere to international standards, ensure high security, and have the potential for economic benefits. The Company encourages relevant personnel to regularly participate in academic conferences and seminars organized by government agencies or trusted medical institutions. Additionally, it establishes action plans for senior executives to present new innovations to the Board of Directors and medical experts, including scientists. This demonstrates the Company's excellent potential in adapting to changes in technology, treatment methods, and medical instruments, and equipment. By continuously selecting and importing new technologies, the Company has achieved a high success rate in treatments and consistently improved its performance. These innovative technologies have gained significant popularity in infertility treatment centers throughout Thailand. The Group is committed to preserving this capability to ensure continuous operations and development consistent with its strategic and business objectives.

732 · Description: Changes in technologies · Info category: STRATEGIC_RISK
Risk of renewing branch lease agreements

The Company's primary business is providing infertility treatment services. Currently, it operates through 5 branches, namely Gaysorn Amarin Building (Headquarter), and 4 other branches located in key economic areas in Bangkok and each region in Thailand. Next Generation Genomic Company Limited provides genetic laboratory services. Safe Wellness Company Limited operates as a skin and aesthetic clinic service provider under the brand "The Fountain Wellness Centre". The head office, located in the Amarin Tower, has been operational since 5 November 2009.Currently, the headquarter, including the Ram Indra branch and Phuket branch, operate under a short-term lease agreement with a term of 3 years.

The Company may face the risk of lease agreement non-renewal or an increase in rental and service rates. These risks may impact the Company's operational continuity.

Throughout the Company's past operations since its establishment, the owners of the rental spaces have never terminated the Company's lease agreements. Moreover, the Company has the ability to renew the lease agreements at any time. Under the majority of the lease agreements, the Company may negotiate lease renewals upon expiration. The leases include clearly defined rental rate adjustment terms. The Company continues to foster and maintain positive relationships with all lessors by consistently making timely rental payments and faithfully adhering to the terms of the leases.

748 · Description: Property lease agreement execution · Info category: OPERATIONAL_RISK
Risk of dependence on key executives

Since the Company was founded by Dr. Wiwat Quangkananurug, an executive who plays a crucial role in the Company's management, his expertise, knowledge, and reputation as a renowned specialist in reproductive medicine have greatly contributed to the Company's success. Dr. Wiwat Quangkananurug has held the position of Chief Executive Officer for over 15 years, as well as Chief Medical Officer and Executive Director. The Company's operations have largely relied on the decisions made by the management, including the direction of business growth, adoption of new medical technologies and innovations, and the selection of the medical team.

  1. The loss of key executives may result in delays in management, policy formulation, or strategic decision-making, and may affect the continuity of the Company’s operations.

  2. In the absence of suitably qualified successors with sufficient understanding of the business, the execution of strategies or business plans may not achieve the intended objectives.

  3. Unexpected changes in key executives may also adversely affect the confidence of shareholders, investors, employees, and other stakeholders in the Company’s stability and strategic direction

The Group acknowledges the potential risks and has implemented an adequate internal control system. It has also established guidelines for risk reduction in accordance with the criteria specified in the Capital Market Supervisory Board's notification. The Company has a well-defined organizational structure that specifies the scope of authority, responsibilities, and approval authority for each position and department. It also has a system in place to carefully select personnel with relevant experience and suitability for their respective positions. The Group has also implemented a succession plan to effectively manage personnel, ensuring a suitable decentralization of power and mitigating the risks. Furthermore, the Group benefits from a management team comprising predominantly long-term employees who have been working with the Group for an average of over 10 years, including physicians and key medical personnel. This tenure ensures that they possess extensive experience, knowledge, and a deep understanding of the infertility service business.

738 · Description: Reliance on employees in key positions · Info category: OPERATIONAL_RISK

Risks to Securities Holders' Investment

Risk Register

Risk NameRisk CharacteristicsConsequencesManagement MeasuresRelated Risk Factors
Risk from major shareholders collectively holding shares exceeding 50.00%

Now, Dr. Wiwat Quangkananurug and his family will be a major shareholder collectively holding 186,021,000 shares, representing 61.20% of shareholding in the Company. Their substantial shareholding significantly influences setting management policies in any one direction. This majority holding also enables them to control the Company's policies and management, including the authority to approve resolutions at a general meeting of shareholders that require a majority vote.

  1. The Company’s decision-making may be primarily influenced by major shareholders. As a result, certain decisions may not equally reflect the interests of all shareholders and may not align with the long-term interests of the Company or its shareholders as a whole.

  2. Minority shareholders may be unable to consolidate sufficient voting power to effectively monitor or counterbalance proposals made by major shareholders.

  3. In the absence of appropriate checks and balances, this may adversely affect transparency, investor confidence, and the overall attractiveness of the Company as an investment.

The Company acknowledges these risks and has included in its Board of Directors three independent directors who serve as members of the Audit Committee. Their role is to audit and balance the operations of the Board of Directors and the Company's executives. All members of the Audit Committee are highly qualified and widely recognized in society. The management structure has clearly and transparently defined the scope of authority, responsibilities, and duties of various committees. Additionally, comprehensive measures have been established, and the Board of Directors recognizes the importance of complying with policies related to the principles of good corporate governance. The Company will strictly comply with the principles of good corporate governance. Furthermore, the Company has established clear boundaries of authority and an approval authority table for each level of transactions within appropriate scopes or monetary limits, including those involving major shareholders, individuals with controlling powers, and potential conflicts of interest.

768 · Description: Return from investment of securities holder · Info category: HOLDER_RISK
Contents